Enterprise Value

-14.43M

Cash

43.35M

Avg Qtr Burn

-4.716M

Short % of Float

0.19%

Insider Ownership

18.78%

Institutional Own.

8.91%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
LSTA12 (HONEDRA®) Details
Critical limb ischemia

Phase 3

Update

LSTA1 Details
Pancreatic cancer, Cancer

Phase 2b

Data readout

LSTA1 + temozolomide Details
Cancer, Glioma, Glioblastoma

Phase 2a

Data readout

LSTA1 + Standard of care Details
Cancer, Solid tumor/s, Esophageal cancer, Cholangiocarcinoma, Head and neck cancer

Phase 2a

Data readout

LSTA1 + nivolumab/FOLFIRINOX, Details
Cancer, Gastroesophageal adenocarcinomas

Phase 1/2

Data readout

Phase 1/2

Data readout

LSTA1 + FOLFIRINOX (neoadjuvant) + panitumumab Details
Cancer, Pancreatic cancer, Colorectal cancer

Phase 1/2

Data readout

Phase 1/2

Data readout

LSTA201 (CLBS201) Details
Chronic kidney disease

Failed

Discontinued

XOWNA (CLBS16) Details
Coronary Microvascular Dysfunction

Failed

Discontinued

Failed

Discontinued